Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
Davina Gale, Katrin Heider, Andrea Ruiz-Valdepeñas, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 500-510
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, et al.
Nature (2023) Vol. 616, Iss. 7957, pp. 553-562
Open Access | Times Cited: 163
Embracing cancer complexity: Hallmarks of systemic disease
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 103
Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial
Richard D Neal, Peter Johnson, Christina A. Clarke, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4818-4818
Open Access | Times Cited: 97
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Marla Lipsyc-Sharf, Elza C. de Bruin, Katheryn Santos, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 22, pp. 2408-2419
Open Access | Times Cited: 90
Practical recommendations for using ctDNA in clinical decision making
Stacey A. Cohen, Minetta C. Liu, Alexey Aleshin
Nature (2023) Vol. 619, Iss. 7969, pp. 259-268
Closed Access | Times Cited: 63
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Xiaosha Wen, Huijie Pu, Quan Liu, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6025-6025
Open Access | Times Cited: 38
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer
Kezhong Chen, Fan Yang, Haifeng Shen, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1749-1762.e6
Open Access | Times Cited: 35
Cell-free DNA approaches for cancer early detection and interception
Jamie E. Medina, Nicholas C. Dracopoli, Peter B. Bach, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e006013-e006013
Open Access | Times Cited: 32
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
Jonathan Dao, Patrick Conway, Baskaran Subramani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13219-13219
Open Access | Times Cited: 31
Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease
Yun Li, Guanchao Jiang, Wendy Wu, et al.
EBioMedicine (2023) Vol. 91, pp. 104553-104553
Open Access | Times Cited: 27
Recommendations for Cell-Free DNA Assay Validations
Christina M. Lockwood, Laetitia Borsu, Milena Cankovic, et al.
Journal of Molecular Diagnostics (2023) Vol. 25, Iss. 12, pp. 876-897
Open Access | Times Cited: 25
Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer—evaluation in a nationwide Danish cohort
Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 229-239
Open Access | Times Cited: 24
Network approach in liquidomics landscape
Daniele Santini, Andrea Botticelli, Antonio Galvano, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 21
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
Hai T. Tran, Simon Heeke, Sheeba J. Sujit, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 183-189
Open Access | Times Cited: 21
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer
Aaron C. Tan, Gillianne Lai, Stephanie P.L. Saw, et al.
Cancer (2024) Vol. 130, Iss. 10, pp. 1758-1765
Open Access | Times Cited: 10
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 5, pp. 495-511
Open Access | Times Cited: 7
Development of new techniques and clinical applications of liquid biopsy in lung cancer management
Kezhong Chen, Yue He, Wenxiang Wang, et al.
Science Bulletin (2024) Vol. 69, Iss. 10, pp. 1556-1568
Open Access | Times Cited: 6
A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology
Gaetano Rocco, Giorgio Pennazza, Kay See Tan, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 9, pp. 1272-1283
Closed Access | Times Cited: 6
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh, Darren Hodgson, Gary J. Doherty, et al.
Trends in cancer (2024) Vol. 10, Iss. 7, pp. 643-654
Open Access | Times Cited: 6
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M. Awad, Patrick M. Forde, Nicolas Girard, et al.
Journal of Clinical Oncology (2025)
Closed Access
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
James R. Black, Gábor Bartha, Charles W. Abbott, et al.
Nature Medicine (2025)
Open Access
Circulating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study
Jiaolin Zhou, Lifeng Li, Yuxin Liu, et al.
EBioMedicine (2025) Vol. 112, pp. 105548-105548
Closed Access
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas
Amanda Frydendahl, Adam J. Widman, Nadia Øgaard, et al.
Molecular Oncology (2025)
Open Access
Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis
Shuyi Niu, Tie Sun, Mozhi Wang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top